Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women.

Hämmerle SP, Mindeholm L, Launonen A, Kiese B, Loeffler R, Harfst E, Azria M, Arnold M, John MR.

Bone. 2012 Apr;50(4):965-73. doi: 10.1016/j.bone.2012.01.009. Epub 2012 Jan 25.

PMID:
22289659
2.

Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.

Sturmer A, Mehta N, Giacchi J, Cagatay T, Tavakkol R, Mitta S, Fitzpatrick L, Wald J, Trang J, Stern W.

Clin Pharmacokinet. 2013 Nov;52(11):995-1004. doi: 10.1007/s40262-013-0083-4.

PMID:
23719683
3.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human parathyroid hormone (1-34) in healthy Chinese subjects.

Liu Y, Yang C, Li Z, Zhou J, Lv Y, Zhang Y, Zeng F, Shi S.

Clin Ther. 2014 Jun 1;36(6):940-52. doi: 10.1016/j.clinthera.2014.03.015. Epub 2014 Apr 29.

PMID:
24793535
4.

AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women.

John MR, Harfst E, Loeffler J, Belleli R, Mason J, Bruin GJ, Seuwen K, Klickstein LB, Mindeholm L, Widler L, Kneissel M.

Bone. 2014 Jul;64:204-10. doi: 10.1016/j.bone.2014.04.015. Epub 2014 Apr 24.

PMID:
24769332
5.

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA.

Bone. 2013 Mar;53(1):160-6. doi: 10.1016/j.bone.2012.11.045. Epub 2012 Dec 9.

PMID:
23234813
6.

Pharmacokinetics, pharmacodynamics, and tolerability of a generic formulation of exenatide: a randomized, open-label, single- and multiple-dose study in healthy Chinese volunteers.

Shi S, Liu Y, Li Z, Wu J, Zhou X, Zeng F.

Arzneimittelforschung. 2012 Feb;62(2):75-82. doi: 10.1055/s-0031-1295484. Epub 2012 Feb 16.

PMID:
22344551
7.

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

Leder BZ, O'Dea LS, Zanchetta JR, Kumar P, Banks K, McKay K, Lyttle CR, Hattersley G.

J Clin Endocrinol Metab. 2015 Feb;100(2):697-706. doi: 10.1210/jc.2014-3718. Epub 2014 Nov 13.

PMID:
25393645
8.

Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.

Chen C, Bujanover S, Kareht S, Rapoport AM.

Headache. 2015 Feb;55(2):265-75. doi: 10.1111/head.12483. Epub 2014 Dec 24.

PMID:
25546369
9.

Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis.

Satterwhite J, Heathman M, Miller PD, Marín F, Glass EV, Dobnig H.

Calcif Tissue Int. 2010 Dec;87(6):485-92. doi: 10.1007/s00223-010-9424-6. Epub 2010 Oct 16.

10.

Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.

Ste-Marie LG, Schwartz SL, Hossain A, Desaiah D, Gaich GA.

J Bone Miner Res. 2006 Feb;21(2):283-91. Epub 2005 Oct 31.

12.

Teriparatide: a review.

Quattrocchi E, Kourlas H.

Clin Ther. 2004 Jun;26(6):841-54. Review.

PMID:
15262455
13.

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women.

Shiraki M, Sugimoto T, Nakamura T.

Osteoporos Int. 2013 Jan;24(1):219-26. doi: 10.1007/s00198-012-2159-7. Epub 2012 Oct 24.

14.

Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy.

Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H.

J Bone Miner Metab. 2012 May;30(3):326-37. doi: 10.1007/s00774-011-0314-4. Epub 2011 Sep 21.

PMID:
21938381
16.

Pharmacokinetics of oral cyanocobalamin formulated with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC): an open-label, randomized, single-dose, parallel-group study in healthy male subjects.

Castelli MC, Wong DF, Friedman K, Riley MG.

Clin Ther. 2011 Jul;33(7):934-45. doi: 10.1016/j.clinthera.2011.05.088. Epub 2011 Jul 1.

PMID:
21722960
18.

Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.

Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.

J Bone Miner Res. 2004 Sep;19(9):1531-8. Epub 2004 Jul 26.

19.

Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers.

Liu Y, Shi S, Wu J, Li Z, Zhou X, Zeng F.

Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):154-61. doi: 10.1111/j.1742-7843.2011.00768.x. Epub 2011 Aug 18.

20.

Metabolism and disposition of the oral absorption enhancer 14C-radiolabeled 8-(N-2-hydroxy-5-chlorobenzoyl)-amino-caprylic acid (5-CNAC) in healthy postmenopausal women and supplementary investigations in vitro.

Gschwind HP, Glaenzel U, Waldmeier F, Wirz B, Sabia HD, Picard F, Weiss HM, Choi L, Swart PJ, Vasudevan A, Azria M.

Eur J Pharm Sci. 2012 Aug 30;47(1):44-55. doi: 10.1016/j.ejps.2012.04.023. Epub 2012 May 8.

PMID:
22579664

Supplemental Content

Support Center